Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.64 |
| ▸ | HTR1A | P08908 | 8/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5459289 | 0.86 | SLC6A2 (0.59) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL5482984 | 0.85 | SLC6A2 (0.58) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| SCHEMBL23842635 | 0.85 | SLC6A4 (0.60) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL69882 | 0.83 | SLC6A4 (0.59) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| SCHEMBL3080032 | 0.82 | SLC6A2 (0.57) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL4095144 | 0.81 | SLC6A2 (0.56) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| SCHEMBL28534399 | 0.80 | SLC6A2 (0.49) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| SCHEMBL2299492 | 0.79 | SLC6A2 (0.64) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| SCHEMBL10840440 | 0.78 | SLC6A2 (0.47) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| SCHEMBL10840428 | 0.78 | SLC6A2 (0.47) | SLC6A2HTR1ASLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | SLC6A2 475/4885HTR1A 391/4885SLC6A3 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.